Medical devices and healthcare corporation Abbott Laboratories (NYSE:ABT) recently announced that its new cardiac mapping platform, the EnSite™ X EP System with EnSite Omnipolar Technology (OT), has received clearance from the U.S. Food and Drug Administration (FDA). The mapping platform is aimed at assisting doctors to better treat abnormal heart rhythms. Following the news, shares of the company declined 1.5% on Wednesday. The stock pared its loss slightly to close at $133.76 in the extended trading session.
https://www.tipranks.com/news/abbotts-cardiac-mapping-system-receives-fda-approval?utm_source=advfn.com&utm_medium=referral
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
Von Mai 2022 bis Jun 2022 Click Here for more Abbott Laboratories Charts.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
Von Jun 2021 bis Jun 2022 Click Here for more Abbott Laboratories Charts.